90.30 USD
-2.00 (-2.17%)
AT CLOSE (11:59 AM EDT)
Incyte Genomics Inc (INCY)
NASDAQ: INCY • USD
90.28
-0.02 (-0.02%)
POST MARKET (AS OF 07:57 PM EDT)
Market: CLOSED
Open?$92.28
High?$92.50
Low?$90.20
Prev. Close?$90.30
Volume?1.5M
Avg. Volume?1.7M
VWAP?$91.07
Rel. Volume?0.89x
Bid / Ask
Bid?$90.27 × 100
Ask?$90.40 × 100
Spread?$0.13
Midpoint?$90.34
Valuation & Ratios
Market Cap?18.0B
Shares Out?199.0M
Float?165.1M
Float %?83.0%
P/E Ratio?13.97
P/B Ratio?3.48
EPS?$6.47
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?3.32Strong
Quick Ratio?3.25Strong
Cash Ratio?2.04Strong
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUED
Score89/100
P/E?14.0CHEAP▾
P/B?3.48FAIR▾
P/S?3.50FAIR▾
P/FCF?13.3CHEAP▾
EV/EBITDA?10.4CHEAP▾
EV/Sales?2.90CHEAP▾
Returns & Efficiency
ROE?24.9%STRONG▾
ROA?18.5%STRONG▾
Cash Flow & Enterprise
FCF?$1.4B
Enterprise Value?$14.9B
Related Companies
Loading...
News
Profile
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Employees
2.8K
Market Cap
18.0B
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Website
Listed
1993-11-03
Address
1801 AUGUSTINE CUT-OFF
WILMINGTON, DE 19803
Phone: (302) 498-6700
WILMINGTON, DE 19803
Phone: (302) 498-6700